I should emphasize POTENTIAL
First they have to show side effects close to Fosrenol ( its bioequivalnt ) in a dialysis population ....pivotal data due Q2 ...next catalyst is the Co announcing the trial is fully enrolled
Then they have to price it so patient copays are reasonable.......something ARDX failed to do with Xphazoh
Note about the trial . Goal is to get serum phosphorous below 5 .
I think they will go slow ( increase dose slowly ) to minimize side effects .
My wife currently prescribes some Fosrenol , and thinks OLC could be a game changer as its one small pill with meals that can be swallowed not chewed .
Patients hate having to chew phosphate binders following a meal. ....so adherence is poor .
Re pricing . Most dialysis patients are on limited income ...they are in a dialysis chair 3 days a week ... 4 hrs at a time ...so 2 of those days are work week days .
So most rely on generics ...Sevelamer for instance ...but hate them as large pills etc etc .
So if approved pricing must be affordable.
Vivo Capital own about 10% of the Co . They are huge in SLNO that I told U about , and also significant position in RZLT ( think I'll start a position )
VKTX ...I have a position in that . Current take over spec , data due soon .
Good luck
Not investment advice etc etc
Kiwi
Recent UNCY News
- Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 • GlobeNewswire Inc. • 10/14/2024 11:03:00 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/11/2024 08:02:13 PM
- Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers • GlobeNewswire Inc. • 10/09/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 • GlobeNewswire Inc. • 09/24/2024 11:03:00 AM
- Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 • GlobeNewswire Inc. • 09/16/2024 11:03:00 AM
- Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 11:03:00 AM
- Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis • GlobeNewswire Inc. • 09/03/2024 11:03:00 AM
- Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 • GlobeNewswire Inc. • 08/26/2024 11:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:15:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:11:52 PM
- Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 11:10:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:05:53 AM
- Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO) • GlobeNewswire Inc. • 07/17/2024 11:03:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/17/2024 04:15:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/16/2024 02:31:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:15:11 PM
- Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • GlobeNewswire Inc. • 07/11/2024 11:03:00 AM
- Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 07/10/2024 11:03:00 AM
- Unicycive Therapeutics Joins Russell Microcap® Index • GlobeNewswire Inc. • 07/01/2024 11:03:00 AM
- Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial • GlobeNewswire Inc. • 06/25/2024 11:30:00 AM
- Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress • GlobeNewswire Inc. • 05/28/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference • GlobeNewswire Inc. • 05/23/2024 11:03:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM